AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
30 Winter Street
Boston
Massachusetts
02108
United States
457 articles about AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
-
Dyax Corp. and AVEO Pharmaceuticals, Inc. Announce Antibody Library License Agreement
7/22/2008
-
AVEO Pharmaceuticals, Inc. Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients with Metastatic Renal Cell Carcinoma
5/29/2008
-
AVEO Pharmaceuticals, Inc. Granted Patent for Unique Genetic Screen to Identify Novel Cancer Drug Targets
5/22/2008
-
AVEO Pharmaceuticals, Inc. to Present at the 2008 Citi Investment Research Global Health Care Conference
5/15/2008
-
AVEO Pharmaceuticals, Inc. to Participate in Leerink Swann and Company Solid Tumors Roundtable Conference
5/2/2008
-
AVEO Pharmaceuticals, Inc.' Novel Triple VEGF Receptor Inhibitor Shows Tumor Regression in Patients with Advanced Renal Cancer; Clinical Activity and Tolerability in other Solid Tumors including Colon and Lung Cancers
4/15/2008
-
New Clinical Data on AVEO Pharmaceuticals, Inc.' Investigational Triple VEGFR Small Molecule Inhibitor AV-951 to be Presented at American Association for Cancer Research Annual Meeting
4/8/2008
-
AVEO Pharmaceuticals, Inc. to Present at the Future Leaders in the Biotech Industry Conference
3/20/2008
-
AVEO Pharmaceuticals, Inc. to Present at the Cowen and Company 28th Annual Health Care Conference
3/12/2008
-
AVEO Pharmaceuticals, Inc. to Present at the 10th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/5/2008
-
AVEO Pharmaceuticals, Inc. Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma
1/31/2008
-
AVEO Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
1/30/2008
-
AVEO Pharmaceuticals, Inc. Appoints Kenneth M. Bate to Board of Directors
1/3/2008
-
AVEO Pharmaceuticals, Inc. to Present at 26th Annual JPMorgan Healthcare Conference
1/2/2008
-
AVEO Pharmaceuticals, Inc. and Eli Lilly and Company Sign Collaboration for Clinical Drug Response Project
12/4/2007
-
AVEO Pharmaceuticals, Inc. to Present at Lazard Capital Markets 4th Annual Healthcare Conference
11/20/2007
-
Preclinical Data Published in Cancer Science Show AVEO Pharmaceuticals, Inc.'s Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers
11/13/2007
-
Results from Phase 1 Study of AVEO Pharmaceuticals, Inc.'s Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease
11/6/2007
-
AVEO Pharmaceuticals, Inc. Appoints New Chief Financial Officer
11/1/2007
-
GeneGo, Inc. Licenses MetaCore Data Analysis Suite to AVEO Pharmaceuticals, Inc.
10/23/2007